{
    "63f57d9b33942b094c000004_001": "tryptophan",
    "63f57d9b33942b094c000004_002": "tryptophan",
    "6450ec0c57b1c7a31500008f_001": "frataxin",
    "644ef46557b1c7a315000083_001": "Oncogenes",
    "6432fdd857b1c7a315000020_001": "autosomal dominant",
    "6450ede757b1c7a315000090_001": "first or second decade",
    "63f03d58f36125a42600001f_001": "hip fractures",
    "63f03d58f36125a42600001f_002": "fracture",
    "63f03d58f36125a42600001f_003": "Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3: HEMI - An Abridged Protocol.",
    "63f03d58f36125a42600001f_004": "hip fracture",
    "644008a657b1c7a31500003f_001": "Omaveloxolone",
    "644640de57b1c7a31500006b_001": "loss of the SMN1 gene in most cases or mutations in rare cases.",
    "644640de57b1c7a31500006b_002": "defects in the survival motor neuron 1 (SMN1) gene.",
    "644640de57b1c7a31500006b_003": "Loss or deletion of survival motor neuron 1 gene (SMN1)",
    "644640de57b1c7a31500006b_004": "mutations",
    "64403a5857b1c7a31500004c_001": "phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks",
    "64402bb057b1c7a315000043_001": "Randomized",
    "64402bb057b1c7a315000043_002": "phase I/II",
    "63eef8d6f36125a42600000f_001": "malaria",
    "63eef8d6f36125a42600000f_002": "malaria",
    "63eef8d6f36125a42600000f_003": "antimalarial",
    "64121f44201352f04a000037_001": "proteolysis targeting chimeras",
    "64121f44201352f04a000037_002": "proteolysis targeting chimera",
    "6451029f57b1c7a315000094_001": "1:40,000",
    "6432f5f257b1c7a31500001c_001": "BTK",
    "6432f5f257b1c7a31500001c_002": "BTK",
    "6440420857b1c7a315000050_001": "Cabotegravir Extended-Release Injectable Suspension",
    "6440420857b1c7a315000050_002": "HIV-1 pre-exposure prophylaxis",
    "6440420857b1c7a315000050_003": "PrEP",
    "6440420857b1c7a315000050_004": "cabotegravir ER injectable suspension",
    "63eef4f5f36125a42600000b_001": "multiple sclerosis",
    "63eef4f5f36125a42600000b_002": "multiple sclerosis",
    "63eef4f5f36125a42600000b_003": "MS",
    "63eef4f5f36125a42600000b_004": "Relapsing Multiple Sclerosis",
    "63eef4f5f36125a42600000b_005": "multiple sclerosis",
    "63eef4f5f36125a42600000b_006": "multiple sclerosis",
    "63eef4f5f36125a42600000b_007": "CD20",
    "63eef4f5f36125a42600000b_008": "pathogenic cell populations.",
    "640c842f201352f04a000025_001": "liver palms",
    "64468b0757b1c7a315000070_001": "poly[A]) binding protein nuclear 1 gene (11-18 repeats in OPMD instead of the normal 10 repeats).",
    "64468b0757b1c7a315000070_002": "PABPN1 gene.",
    "63f0494cf36125a426000028_001": "Respiratory Syncytial Virus",
    "63f0494cf36125a426000028_002": "RSV",
    "63f0494cf36125a426000028_003": "respiratory syncytial virus",
    "63f0494cf36125a426000028_004": "RSV",
    "63f0494cf36125a426000028_005": "respiratory syncytial virus",
    "63f0494cf36125a426000028_006": "respiratory syncytial virus",
    "640ddbe9201352f04a000027_001": "durvalumab",
    "640ddbe9201352f04a000027_002": "durvalumab",
    "640ddbe9201352f04a000027_003": "durvalumab",
    "644e81fa57b1c7a315000079_001": "Tumor-suppressor genes (TSGs) or antioncogenes",
    "644e81fa57b1c7a315000079_002": "tumour suppressor proteins",
    "644e81fa57b1c7a315000079_003": "tumor suppressor genes",
    "6415c7fb690f196b51000016_001": "September 4, 2014",
    "64468e0d57b1c7a315000071_001": "1 in 80,000 individuals worldwide",
    "63f04716f36125a426000025_001": "angioedema",
    "63f04716f36125a426000025_002": "angioedema",
    "63f04716f36125a426000025_003": "HAE",
    "644ec7fe57b1c7a315000082_001": "The lac operon",
    "644ec7fe57b1c7a315000082_002": "colilac operon.",
    "63fa16d8201352f04a000002_001": "colorectal cancer",
    "63fa16d8201352f04a000002_002": "CRC",
    "6451060c57b1c7a315000096_001": "Kennedy's disease is nearly exclusively caused by mutations in the androgen receptor encoding gene (AR).",
    "6451060c57b1c7a315000096_002": "androgen receptor (AR) gene, and mutant AR is presumed to act in motoneurons to cause SBMA.",
    "6451060c57b1c7a315000096_003": "androgen receptor (AR) gene.",
    "61f7c904882a024a10000027_001": "asthma",
    "61f7c904882a024a10000027_002": "asthma",
    "61f7c904882a024a10000027_003": "asthma",
    "61f7c904882a024a10000027_004": "asthma",
    "61f7c904882a024a10000027_005": "asthma",
    "61f7c904882a024a10000027_006": "eosinophilic asthma",
    "61f7c904882a024a10000027_007": "asthma",
    "61f7c904882a024a10000027_008": "Asthma",
    "61f7c904882a024a10000027_009": "asthma",
    "644ef78f57b1c7a315000084_001": "nucleoprotein complex called chromatin in a manner that enables it to be rapidly accessed during genomic processes.",
    "644ef78f57b1c7a315000084_002": "chromatin fibres, and tethering of chromosomal regions to nuclear structures.",
    "644298cc57b1c7a315000062_001": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine",
    "644298cc57b1c7a315000062_002": "FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1.",
    "6442933f57b1c7a315000060_001": "partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4",
    "6442933f57b1c7a315000060_002": "Facial-scapular-humeral myodystrophy Landouzy-Dejerine"
}
